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Forward-looking statements 
This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). 
Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the 
opinions expressed are fair and reasonable, the contents of this presentation have not been formally verified by Oxford 
BioMedica plc (the “Company”) or any other person. Accordingly, no representation or warranty, expressed or implied,  
is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this 
presentation, and no reliance should be placed on such information or opinions. Further, the information in this 
presentation is not complete and may be changed. Neither the Company nor any of its respective members, directors, 
officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use 
of such information or opinions or otherwise arising in connection with this presentation.  
 
This presentation may contain forward-looking statements that reflect the Company's current expectations regarding 
future events, its liquidity and results of operations and its future working capital requirements. Forward-looking 
statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend 
on a number of factors, including the success of the Company's development strategies, the successful and timely 
completion of clinical studies, securing satisfactory licensing agreements for products, the ability of the Company to obtain 
additional financing for its operations and the market conditions affecting the availability and terms of such financing.  
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Problem statement 
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• Gene and cell therapy revolution  
• £9 -14 bn by 2025, growing to £21-32 bn by 
2030 
• Market expansion boosted by recent approvals, 
driving significant investme t in the sector 
• Gene & gene-modified cell therapy sector raised 
$7.8 Bn YTD 2018 (34% increase YOY) 
Source: Q3 2018 Data Report, Alliance for Regenerative Medicine  
 
• Surge in demand for lentiviral vectors  
• Greatly underpinned by the success of the T-cell 
therapies and rapidly growing clinical pipeline  
• OXB  estimates the lentiviral vector bioprocessing 
market 
• $200m in 2017 and will grow to $800m by 2026 
 
 
 
 Source: Oxford BioMedica management estimates 
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Agenda 
1 Company overview & facilities 
 
2 
3 
5 
6 
7 Development of advanced process analytical technologies  
8 Concluding remarks 
LentiVector® gene delivery platform 
Suspension process development – USP considerations 
 
Manufacturing strategy consid rations 
           – DSP considerations 
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4 Scale-up & manufacturing challenges 
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Oxford BioMedica – An overview 
>20 years as a specialist in lentiviral vectors 
• Founded in 1996, based in Oxford, UK, IPO on LSE April 2001 (OXB.L) 
• Mission – Delivering life-changing gene therapies to patients  
• Core LentiVector® technology platform based on lentiviral vector in vivo 
and ex vivo gene delivery system 
• 1st world-wide to administer lentiviral vector gene therapy in vivo (both brain and eye) 
• 1st approved advanced therapy in the US using LentiVector® enabled technology,                                          
[Novartis’s KYMRIAH® (tisagenlecleucel)] 
• 1st commercial supplier of lentiviral vectors, post CAR-T approval 
• >400 patients treated by Oxford BioMedica or by its partners  
• Four Phase I/II studies completed with encouraging patient safety and efficacy 
      gene delivery platform 
• IP – extensive IP comprising both patents and know-how 
• Facilities – state-of-the-art bioprocessing and laboratory facilities 
• Employees – >400 full time employees 
• Capabilities – Development, Manufacture, Analytics, Quality (lentiviral vectors) 
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Oxford BioMedica facilities in the UK 
Yarnton   
18,300 sq.ft (1,700 sq. m) 
 GMP production facility 
 Two clean room suites 
 GMP QC microbiology laboratory 
 1Q2019 implementation of suspension 
platform 
 
Windrush Court  
 Corporate HQ & Laboratories 
       71,955 sq.ft (6,684 sq.m) 
 GMP Warehous  Hub 
       2,691 sq.ft (250 sq.m) 
 GMP QC Release & stability testing facilities 
 
Harrow House & Chancery Gate 
19,375 sq.ft (1,800 sq.m) 
 GMP production facility 
 Two clean room suites 
 GMP QC microbiology laboratories 
 Raw material testing 
 GMP cold chain warehouse & office space 
Source: https://resources.oncourse.iu.edu/access/content/user/leema/profilepage/oxford.html 
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Oxford BioMedica facilities in the UK 
Source: https://resources.oncourse.iu.edu/access/content/user/leema/profilepage/oxford.html 
The Future “OXBox”  
        84,000 sq.ft (7,800 sq.m).  
 Phase I – 45,000 sq. ft (4,200 sq. m) 
 GMP production facility 
 Four clean room suites 
 Two Fill & Finish suites 
 Offices, warehousing and QC 
laboratories 
 
Innovation Centre  
 33,000 sq.ft (3,066 sq. m) 
 Located adjacent to Windrush Court 
 Offices & Laboratories 
 Allows for further expansion of R&D 
and platform innovation activities on 
one site 
(Under construction – operational early 2020) 
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Strategy: Leveraging our                            delivery platform 
Partners’ Programmes OXB products 
IP – patents and know-how    |    Facilities    |    Expertise    |    Quality systems 
Multiple 
income 
streams 
R&D Investment 
Technical Developments 
Investment  into internal 
& external assets up to 
early clinical stage 
Product 
development 
LentiVector® Platform 
Process 
development 
fees 
Process 
development 
incentives 
Bio-
processing 
revenues 
Royalties 
Upfront & 
milestones 
Royalties 
Development 
funding 
Spin out/ 
out-
licence 
Platform and 
process 
development 
Technical and scientific 
knowledge transfer 
Arising IP Arising IP 
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Product 
development 
partner 
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Gene and cell therapy technologies 
Oxford BioMedica is involved at early stage of development of lentiviral 
based products either our own or with partners – strong IP position  
Oxford BioMedica’s LentiVector® Platform 
Haemophilia 
In vivo & Ex vivo development 
• Direct administration in vivo of lentiviral vectors to target organs 
such as the eye, brain, liver and lung  
• Administration ex vivo to target stem cells, T-cells and other 
cell types 
• Permanent modification of dividing and non-dividing cells 
• Broad tissue tropism 
• Single administration with sustained or permanent efficacy 
• No toxicity or adverse immune reaction 
 
Lentiviral vectors vs AAV vectors 
 
 
 
 
 
 
 
AAV Vectors Lentiviral Vectors 
• Efficient in vivo gene 
delivery 
• Safe and well 
tolerated 
 
• Large therapeutic 
payload 
 
• No pre-existing 
immunity 
 
• Permanent 
modification of 
dividing cells 
 
• IP protection 
 
• Ease of manufacture 
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Mutated WPRE 
SIN-LTR 
Codon-optimised gag-pol 
TRiP 
Technology 
Clinical/commercial 
ready process 
development and 
characterisation 
 
OXB vectors familiar to 
regulators  
Next generation vector 
engineering 
Producer and packaging 
lines 
OXB’s LentiVector® gene delivery platform 
Transient vector production: 
Adherent/serum 
Suspension/serum free 200L 
bioreactors 
State of  
the art DSP & 
2000x concn 
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OXB LentiVector® platform – safety features 
Minimal LentiVector system 
• Third generation 
• Separated on 4 plasmids with 
minimal sequence homology 
Genome cassette 
• Minimal viral nucleic acid (RNA) 
remaining 
• No viral open reading frames or 
lentiviral enhancers 
• Self inactivating LTR 
• Mutated WPRE 
Gag-pol 
• Codon optimised gag-pol 
• No sequence homology with 
genome cassette 
Gag-Pol 
Packaging component 
Envelope cassette 
(Pseudo-typing) 
 
Vector 
Genome  
Rev expression 
cassette 
Contains only ~ 10% (861 bp) of wild type genome 
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• During manufacture, transgene is normally 
expressed 
• Can reduce vector yield activity, and impact 
product purity and yield 
• Ideally transgene express on should be 
repressed to allow consistent vector 
production and purification, irrespective of 
transgene identity 
• Transgene Repression in vector 
Production [TRiP] cell system is used to 
recover vector titres compromised by 
transgene expression 
• Bacterial protein TRAP and RNA binding 
sequence inserted within transgene leader 
sequence 
Potent repression of GFP transgene in cells 
transfected with TRiP system components 
Standard TRiP 
Source: Published PCT number WO 2015/092440 
Maunder HE et al., Nat Coms 2017  
12 
                Transgene Repression In vector Production 
TM 
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                Transgene Repression In vector Production 
TM 
GFP  CAR-T 
HIV-1 
EIAV 
GFP COX-2 
Adeno 
GFP Toxic Gene 
System expected to support any viral 
vector system 
Source: Published PCT number WO 2015/092440 
Maunder HE et al., Nat Coms 2017  
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Producer cell line development 
Transient System 
 
 Does not require select ble 
markers  
 Immediate production 
 Fast development timelines 
 Expensive at large scale 
 Resource intensive 
 Generates cells with varying gene 
expression levels 
 
 
Stable Cell Lines 
 
 Cell ‘combinations’ can be 
engineered to suit purpose 
 Large scale vector production 
over extended periods 
 Reduces batch-to-batch variation 
 Reduces costs 
 Generates clones with high 
expression levels 
? Requires lengthy cell-line stability 
studies  
 Development time and costs can 
be high 
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Proprietary technologies: packaging/producer cell lines 
• HIV packaging & producer cell lines have been 
developed using the ACSS 
• LV production yields are equivalent or better 
that standard transient process 
• New platform is available to partners 
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Phase of clinical 
development 
‘Low demand’ indication ‘High demand’ indication 
No. of subjects Volume (L) No. of subjects Volume (L) 
Preclinical 12 primates  
30-60 rodents  
10-20L 12 primates  
30-60 rodents 
10-20L 
Phase I/II 10 -15 patients 100L 10-20 100-200L 
Phase II 20 200L 50-100 500-1000L 
Phase III 50 500L 100-500 1000L-5000L 
BLA/MAA 
Commercial 
100’s ≥1000L >1000’s >10,000L 
Manufacturing strategy considerations 
Assumptions:   1L gives approximately one dose to account process losses, testing  etc.  
                         USP yield improvements targeted to realise benefits in COGS and access to high demand indications  
Concept 
Research 
In Vitro 
Non-
Clinical 
In Vivo  
Non-GLP 
Non-
Clinical 
GLP 
Clinical 
Phase      
 I & II 
Clinical 
Phase  
III 
BLA/MAA 
Commercial 
RESEARCH DEVELOPMENT 
Real world thinking – hypothetical example 
Potential impact of indication and clinical development phase on production capacity requirements: 
 
• Manufacturing strategies are influenced by indication and development phase 
• Major driver for  process design/development/improvements in upstream volumetric productivity, recovery/downstream 
purification, sterile manufacturing, % step recoveries etc. 
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Suspension platform 
 
Easy to scale-up  
Up to 2m3 in SUB format  
Serum-free 
Batch/fed-batch or perfusion 
Process simplification, 
on-line monitoring, reduced 
manipulations, lower risk 
profile 
Planar 
technologies 
Scale-out based 
on surface area 
Serum-containing  
 
More laborious, 
time consuming, 
limited monitoring 
of mono-layer, 
multiple 
manipulations, 
higher risk profile 
Nunc™ Automatic  Cell 
Factory™ System   
CF-40 tray systems 
25,280cm² 
Scale-out 
2D Planar  
technologies 
Nunc™ Cell Factory™ Systems  
CF-10 tray systems, 6,320 cm2o 
HYPERStack™ Vessels 
HS-12/HS-36, 6,000/18,000cm2 
T-225 Flasks 
225cm2 
Scale-up 
Suspension  
platform 
Production cells 
20µm 
5L bioreactor 
200L single-use  
bioreactor 
50L single-use 
 bioreactor 
Scale-up 
Fixed-bed 
Systems 
0.53-4m2 single-use Fixed–bed bioreactor 
66-500m2 single-use  
Fixed-bed bioreactor 
Process evolution of the LentiVector® manufacturing platform  
Late clinical & commercial supply options 
Transient, packaging 
& producer cell line 
development 
Current adherent 
process with serum  
0.5L bioreactor 
Shake flask 
15 mL ambr™ bioreactor 
mimic 
Fixed-bed 
systems 
Scale-up based on 
fixed bed compaction 
 Serum containing / 
serum-free 
Process simplification,  
on-line monitoring, 
reduced 
manipulations, lower 
risk profile 
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Downstream 
Processing 
Upstream 
Processing 
Production Cells 
OXB vector process development strategies 
Suspension 
culture 
• Animal 
• component free 
• media and feed 
• 100% single use 
Process Con rol 
• pH 
• Temperature 
• Dissolved oxygen 
• Identification of 
critical process 
parameters 
Scale up 
• P/V ratio 
• KLa 
• Tip speed 
• 100% Single use 
Transient 
• Plasmids 
• Tfx reagent 
• Short USP 
phase 
Stable 
• Packaging 
cell line 
• Producer cell 
line 
• Flexible 
• Scalable 
• Gentle 
• 100% single use 
• Rapid, optimised yield 
• Throughput 
• Vmax / Pmax / Tmax 
sizing 
• Membrane chemistry 
compatibility 
• Pore size selection 
• Dynamic binding capacity 
• Buffer selection 
Holistic view of the development of ‘next generation’ lentiviral vector manufacturing 
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Automated, high through-put  
cell line generation  
Stable, high producer  
packaging/producer cell lines 
Vector 
 Media Process 
Analytics Advanced  
Manufacturing  
Platform 
Cells 
Vector design & 
optimisation 
OXB process development roadmap  
Establish media &  
feed platform 
Scale-up  
Studies 
>200L 
Formulation, 
Fill & Finish 
Development of rapid 
analytics for in-process 
& release testing 
Scale up & manufacturing challenges 
Serum-free suspension culture 
in single-use bioreactor 
Purification development 
programme 
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Design and scale-up challenges for lentiviral vector production 
Upstream considerations 
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Slide for large image 
• Access to stable, high producing packaging/producer cell lines 
 Justification for investment in stable cell line development has to be evaluated case by 
case based on predicted patient population size 
 Automation of clone selection process (ACSS) 
• Scale-up of transient transfection processes  
 Development of a stable producer cell line removes this constraint, enabling process 
refinements such as higher cell density, fed-batch and perfusion 
 Optimisation of transfection step using DoE studies 
− Minimises costs (DNA, transfection reagents) on scale up 
 Automation reduces operator-dependence and minimises variability (suspension process) 
• Envelope proteins (such as VSV-G) are often cytotoxic 
 DoE studies to determine optimum plasmid amounts for transfection 
• Other LV packaging components (Rev, Gag/Pol) induce extra metabolic burden 
 Regulation of expression of LV packaging components (Rev, Gag/Pol) 
• Process component toxicity 
 Transfection & induction reagents 
 
Suspension process development – USP considerations 
Overcoming typical cell culture, transfection & scale-up challenges 
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Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 
1, n=3 1x Original Mean 27% 
Max. up to 30% 
Mean 30% 
Max. up to 50% 
Mean 29% 
Max. up to 44% 
Mean 20% 
Max. up to 30% 
2, n=3 2x Original Mean 28% 
Max. up to 53% 
Mean 34% 
Max. up to 53% 
Mean 29% 
Max. up to 56% 
- 
3, n=3 2x Enhanced Mean 26% - - - 
Suspension process development 
 
GMP production 
scale (200L) 
Continuous process improvement  
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Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 
1, n=3 1x Original Mean 27% 
Max. up to 30% 
Mean 30% 
Max. up to 50% 
Mean 29% 
Max. up to 44% 
Mean 20% 
Max. up to 30% 
2, n=3 2x Original Mean 28% 
Max. up to 53% 
Mean 34% 
Max. up to 53% 
Mean 29% 
Max. up to 56% 
- 
3, n=3 2x Enhanced Mean 26% - - - 
Suspension Process Development – DSP considerations 
Functional 
lentiviral 
vector 
Particles 
Vector 
stability 
ignific nt 
concentration of 
gene therapy to 
attain clinical 
efficacy, 
especially for in 
vivo applications   
 
Vector 
heterogeneity 
Process 
related 
impurities 
By-product 
toxicity 
Inactive / 
empty particles 
Aggregates 
VSV-G vesicles / 
TBS Protein 
aggregates 
Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 
1, n=3 1x Original Mean 27% 
Max. up to 30% 
Mean 30% 
Max. up to 50% 
Mean 29% 
Max. up to 44% 
Mean 20% 
Max. up to 30% 
2, n=3 2x Original Mean 28% 
Max. up to 53% 
Mean 34% 
Max. up to 53% 
Mean 29% 
Max. up to 56% 
- 
3, n=3 2x Enhanced Mean 26% - - - 
Lentiviral vector product properties 
• Family: Retroviridae 
• Genus: Lentivirus 
• Enveloped 
• Size: ~ 80 - 120 nm in diameter 
• Genome: Two copies of positive-sense ssRNA inside a 
conical capsid 
• Strong net negative charge 
• Shear sensitivity 
• Temperature sensitivity (inactivation) – product stability 
• Freeze-thaw sensitivity 
• Salt sensitivity (v. narrow range) 
 
 
 
 
Process development and manufacturing challenges 
Empty / inactive 
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Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 
1, n=3 1x Original Mean 27% 
Max. up to 30% 
Mean 30% 
Max. up to 50% 
Mean 29% 
Max. up to 44% 
Mean 20% 
Max. up to 30% 
2, n=3 2x Original Mean 28% 
Max. up to 53% 
Mean 34% 
Max. up to 53% 
Mean 29% 
Max. up to 56% 
- 
3, n=3 2x Enhanced Mean 26% - - - 
• Vector stability 
• Need to develop « soft » production methods 
• Minimise risk of high shear velocities, eddies, gas-liquid interfaces etc. 
• Reduce residence time in chromatography columns by using membrane 
chromatography or alternatives 
 
• Sensitivity to  temperature, pH and high salt, gas-liquid interfaces, shear 
effects 
• Avoid unwarranted intermediate storage steps 
• Minimise overall processing time 
• Add excipients or sugars into final formulation for cryopreservation 
• Develop formulation to stabilise vector at ambient temperature and upon 
freeze-thawing 
Lentiviral vector product properties 
Process development and manufacturing challenges cont’d 
Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 
1, n=3 1x Original Mean 27% 
Max. up to 30% 
Mean 30% 
Max. up to 50% 
Mean 29% 
Max. up to 44% 
Mean 20% 
Max. up to 30% 
2, n=3 2x Original Mean 28% 
Max. up to 53% 
Mean 34% 
Max. up to 53% 
Mean 29% 
Max. up to 56% 
- 
3, n=3 2x Enhanced Mean 26% - - - 
• Sensitivity to high salt concentration 
• Dilute vector after high salt contact as soon as possible 
• Use weak anion-exchangers (DEAE) and milder elution conditions 
• Use flow-through purification methods 
 
• Sterility assurance issues 
• Terminal filtration using one or more 0.2 µm sterilising-grade filters can be 
technically challenging 
• Vector particles are relatively large (e.g. an average diameter of approx. 120 
nm) compared to the maximal pore size of sterilising grade filters (i.e. 200nm) 
• Aggregation – formulation buffer  considerations important 
• Can lead to unacceptable product loss if the product is sterile-filtered at high 
concentration 
Lentiviral vector product properties 
Process development and manufacturing challenges cont’d 
Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 
1, n=3 1x Original Mean 27% 
Max. up to 30% 
Mean 30% 
Max. up to 50% 
Mean 29% 
Max. up to 44% 
Mean 20% 
Max. up to 30% 
2, n=3 2x Original Mean 28% 
Max. up to 53% 
Mean 34% 
Max. up to 53% 
Mean 29% 
Max. up to 56% 
- 
3, n=3 2x Enhanced Mean 26% - - - 
Schematic of Serum-free, Suspension Process (200L Scale) 
GMP manufacturing process for clinical supply  
Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 
1, n=3 1x Original Mean 27% 
Max. up to 30% 
Mean 30% 
Max. up to 50% 
Mean 29% 
Max. up to 44% 
Mean 20% 
Max. up to 30% 
2, n=3 2x Original Mean 28% 
Max. up to 53% 
Mean 34% 
Max. up to 53% 
Mean 29% 
Max. up to 56% 
- 
3, n=3 2x Enhanced Mean 26% - - - 
Sterile Manufacturing Process (Aseptic Fill & Finish) 
GMP manufacturing process for clinical supply  
Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 
1, n=3 1x Original Mean 27% 
Max. up to 30% 
Mean 30% 
Max. up to 50% 
Mean 29% 
Max. up to 44% 
Mean 20% 
Max. up to 30% 
2, n=3 2x Original Mean 28% 
Max. up to 53% 
Mean 34% 
Max. up to 53% 
Mean 29% 
Max. up to 56% 
- 
3, n=3 2x Enhanced Mean 26% - - - 
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Industrial Viral Vector Manufacturing using Advanced Process 
Analytical Technologies  
 
• 2-year £2M collaboration project co-funded by Innovate UK  
• Consortium led by OXB includes the CGTC and Synthace Ltd 
• Apply novel advanced technologies to further evolve OXB’s proprietary suspension 
LentiVector® platform  
• Support intensification of manufacture and drive higher viral titre yields to enable 
maximal productivity whilst limiting the need for increased process scale and higher 
capital costs. 
 Real time in-process monitoring 
 Improved product knowledge 
 Better process understanding and control 
 Improved consistency of manufacture 
 Optimised media and feeding strategies 
 Reduced product cycle times 
 Higher volumetric productivity and yields 
 Reduced COGS 
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Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 
1, n=3 1x Original Mean 27% 
Max. up to 30% 
Mean 30% 
Max. up to 50% 
Mean 29% 
Max. up to 44% 
Mean 20% 
Max. up to 30% 
2, n=3 2x Original Mean 28% 
Max. up to 53% 
Mean 34% 
Max. up to 53% 
Mean 29% 
Max. up to 56% 
- 
3, n=3 2x Enhanced Mean 26% - - - 
30 
• Temp 
• pH 
• DO 
• Raman spectroscopy 
• RI spectroscopy 
Multivariate 
analysis 
Omics analysis 
Transcriptomics 
Big data analytics 
In silico modelling 
Real-time  
in-process monitoring 
Adaptive control 
Industrial Viral Vector Manufacturing using Advanced Process 
Analytical Technologies  
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Concluding remarks 
• Gene and cell therapy has reached the stage where several very promising 
therapies have reached the commercial/market supply phase. However many 
challenges remain. 
• OXB’s know-how and technologies  in lentiviral vector development, production 
and analytics in addition to its ability to manufacture commercial quantities of 
viral vectors, provides significant competitive advantage  
• OXB is a technology innovator with ongoing investment to gain increased 
understanding enabling further improvements to the LentiVector® gene delivery 
platform  
• OXB recently completed a net £19.3m capital raise to fund the construction of 
additional manufacturing capacity (OXBox facility).  
• This investment with Innovate UK viral vector grant support for OXBox will 
enable OXB to maintain its global leading position, and to be well-positioned to 
meet future demand. 
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Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 
1, n=3 1x Original Mean 27% 
Max. up to 30% 
Mean 30% 
Max. up to 50% 
Mean 29% 
Max. up to 44% 
Mean 20% 
Max. up to 30% 
2, n=3 2x Original Mean 28% 
Max. up to 53% 
Mean 34% 
Max. up to 53% 
Mean 29% 
Max. up to 56% 
- 
3, n=3 2x Enhanced Mean 26% - - - 
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